AI and machine learning are revolutionizing drug discovery, development, and lifecycle management, addressing industry ...

NVIDIA and Lilly bring together a world-leading, multidisciplinary team of scientists, AI researchers and engineers to ...

AI therapeutics company built on causal biology, today announced the acquisition of CombinAbleAI and the launch of insitro's TherML™ (Therapeutic Machine Learning) platform. The acquisition, which is ...

AI in drug discovery offers key market opportunities by enhancing drug development efficiency, reducing costs, and improving success rates. It supports personalized medicine, facilitating custom ...

Converge Bio, the AI platform for accelerated drug discovery and development, announced today $25 million in Series A funding ...

In a recent medium.com blog post, Daphne Koller — an artificial intelligence researcher at the Department of Computer Science at Stanford University and, until just a few months ago, chief computing ...

A new global public-private partnership using artificial intelligence (AI) to accelerate drug discovery is launching with UCL as one of the lead ...

insitro has acquired Israeli AI therapeutics company CombinAbleAI and launched its TherML platform, creating an end-to-end, ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, a pioneer in machine learning for drug discovery and development, today announced a new collaboration with Eli Lilly and Company (Lilly) to ...

(L) First and co-corresponding author Charlie Wright, PhD, St. and (R) co-corresponding author Paul Geeleher, PhD, both of the St. Jude Department of Computational Biology. (MEMPHIS, Tenn. – December ...

Forbes contributors publish independent expert analyses and insights. Greg Licholai writes and teaches about innovation in healthcare. In an era where artificial intelligence (AI) is transforming ...